Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Encoberminogene Rezmadenovec

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 554Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XyloCor Therapeutics Dose First Patient in Phase 2b EXACT-2 Trial
    XyloCor Therapeutics Dose First Patient in Phase 2b EXACT-2 Trial

    10 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250710062216/en/First-Patient-Dosed-in-XyloCor-Therapeutics-Phase-2b-EXACT-2-Trial-Evaluating-XC001-for-the-Treatment-of-Coronary-Artery-Disease

    BUSINESSWIRE
    10 Jul 2025
    Share Share
    Exelixis: Zanzalintinib Combo Boosts OS in Colorectal Cancer
    Exelixis: Zanzalintinib Combo Boosts OS in Colorectal Cancer

    22 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250622399674/en/Exelixis-Announces-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-Improved-Overall-Survival-in-STELLAR-303-Phase-3-Pivotal-Trial-in-Patients-with-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    22 Jun 2025
    Share Share
    Exelixis Reports Positive STELLAR-002 Trial Results at ASCO 2025
    Exelixis Reports Positive STELLAR-002 Trial Results at ASCO 2025

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522412302/en/Exelixis-Announces-Encouraging-Results-from-Phase-1b2-STELLAR-002-Trial-Evaluating-Zanzalintinib-in-Combination-with-Immune-Checkpoint-Inhibitors-in-Advanced-Kidney-Cancer-at-ASCO-2025

    BUSINESSWIRE
    22 May 2025
    Share Share
    Exelixis Announces Q3 2024 Financial Results and Update
    Exelixis Announces Q3 2024 Financial Results and Update

    29 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241029473805/en

    BUSINESSWIRE
    29 Oct 2024
    Share Share
    Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial
    Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial

    04 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231201184887/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib

    04 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231203437225/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share